Roche Confirms Tocilizumab (Actemra®) Failed to Meet Endpoints in the Phase 3 COVACTA Study Involving COVID-19 Associated Pneumonia

TrialSite recently suggested based on unfolding study results that repurposed IL-6 inhibitors, such as Roche’s Actemra®/ReActemtra® (tocilizumab), may not work to treat patients infected with COVID-19. TrialSite pointed to the results of an Italian study as a...

Genentech (Roche) Collaborates with BARDA to Launch Actemra Clinical Trial for Adult Patients with Severe COVID-19 Pneumonia

Genentech (Roche) plans a Phase III clinical trial to assess its marketed drug Actemra (tocilizumab) as a treatment for severe cases of COVID-19 in adults. In collaboration with the Biomedical Advanced Research and Development Authority (BARDA), the prominent company...

Pin It on Pinterest